A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

308

Participants

Timeline

Start Date

October 20, 2016

Primary Completion Date

November 27, 2017

Study Completion Date

November 27, 2017

Conditions
Heart Failure
Interventions
DRUG

elamipretide

20 mg elamipretide administered intravenously once daily for 7 consecutive days

DRUG

Placebo

Placebo administered intravenously once daily for 7 consecutive days

Trial Locations (46)

1096

Hungarian Institute Of Cardiology, Department of Adult Cardiology, Budapest

1122

Semmelweis University Heart and Vascular Center, Budapest

1202

"Clinic of Cardiology, Second Multiprofile Hospital for Active Treatement - Sofia EAD", Sofia

1309

"Clinic of Cardiology, Multiprofile Hospital for Active Treatment National Heart Hospital EAD", Sofia

1407

"Clinic of Cardiology, City Clinic University Multiprofile Hospital for Active Treatment EOOD", Sofia

1750

"Clinic of Internal Diseases, Multiprofile Hospital for Active Treatment, Sveta Anna Sofia AD", Sofia

2020

Hospital ZNA Middelheim, Antwerp

5000

"Department of Cardiology, Multiprofile Regional Hospital for Active Treatement Dr. Stefan Cherkezov AD", Veliko Tarnovo

6400

"Department of Internal Diseases, Multiprofile Hospital for Active Treatment Sveta Ekaterina - Dimitrovgrad EOOD", Dimitrovgrad

8000

County St. George University Teaching Hospital, Department of Internal Medicine Cardiology, Székesfehérvár

8900

Zala County Hospital Cardiology Department, Zalaegerszeg

9300

Hospital Onze Lieve Vrouw campus Aalst, Aalst

11000

Clinical Centre of Serbia, Emergency Centre, Belgrade

Clinical Centre of Serbia, Institute for Cardiovascular Diseases, Belgrade

11070

Clinical Hospital Centre Bezanijska kosa, Belgrade

11080

Clinical Hospital Centre Zemun, Belgrade

18000

Clinical Centre Nis, Niš

21204

Institute for Cardiovascular Diseases of Vojvodina, Kamenitz

28007

Hospital General Universitario Gregorio Marañón, Madrid

28040

Hospital Clínico San Carlos, Madrid

31059

CHU de Rangueil, Toulouse

46010

Hospital Clínico Universitario de Valencia, Valencia

46014

Consorci Hospital General Universitari de Valencia, Valencia

46026

Hospital Universitari i Politècnic La Fe, Valencia

94000

Hôpital Henri Mondor, Créteil

LV5417

Daugavpils Regional Hospital, Daugavpils

LV1038

Riga East Clinical University Hospital, Clinic Gailezers, Liepāja

LV3402

Liepaja Regional Hospital, Liepāja

LV1002

Pauls Stradins Clinical University Hospital, Latvian Centre of Cardiology, Riga

5223 GV 's

Hospital Jeroen Bosch, 's-Hertogenbosch

7416 S

Deventer Hospital, Deventer

6716 RP

Hospital Gelderse Vallei, Ede

9713 GZ

University Medical Center Groningen, Groningen

8601 ZR

Hospital Antonius/D&A research Genetic, Sneek

5042 AD

Hospital Elisabeth -Tweesteden, Tilburg

7207 AE

Hospitals Gelre, Zutphen

91-347

Bieganski Provincial Specialist Hospital, Department of Cardiology, Clinic of Cardiology UM, Lodz

04-628

Cardinal Stefan Wyszynski, Institute of Cardiology, Clinic Heart Failure and Transplantation, Warsaw

Cardinal Stefan Wyszynski, Institute of Cardiology, Clinic of Coronary Heart Disease and Structural Heart Disease, Warsaw

15006 A

Complexo Hospitalario Universitario de A Coruña, A Coruña

08907

Hospital Universitario de Bellvitge, Barcelona

28222 Majadahonda

Hospital Universitario Puerta de Hierro Majadahonda, Madrid

36312 Vigo

Hospital Alvaro Cunqueiro, Pontevedra

BD6 6RJ

Bradford Royal Infirmary, Bradford

LE3 9QP

Glenfield Hospital, Leicester

TQ2 7AA

Torbay Hospital, Torquay

All Listed Sponsors
lead

Stealth BioTherapeutics Inc.

INDUSTRY

NCT02914665 - A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure | Biotech Hunter | Biotech Hunter